Clinical trials: Respiratory Virus
Covid19
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
This is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous (IV) Allocetra-OTS 10x10^9 cells vs placebo (1:1) in adult hospitalized patients with severe or…
- Trial name
- NCT04922957
- Testing
- ALLOCETRA-OTS
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Enlivex Therapeutics Ltd.
Asthma
Comparing Efficacy and Safety of Inhaled SNG001 to Placebo
When people with asthma get respiratory virus such as a cold or flu it often increases asthma symptoms. The investigators will test the study medication to find out if it can prevent the virus spreading from the nose to the…
- Trial name
- NCT01126177
- Testing
- Interferon beta 1a
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Synairgen Research Ltd.
Influenza, Orthomyxoviridae Infections
Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults
The trial is a Phase II, open-label trial in healthy subjects aged 18 to 60 years to support the immunogenicity data from previous clinical studies. Objectives: To describe the immune response 21 days after each vaccination.
- Trial name
- NCT00545701
- Testing
- A/H5N1 inactivated, split-virion influenza virus
- Where
- 2 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Common Cold
Mucinex Exploratory Cold Study
This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo.
- Trial name
- NCT01046136
- Testing
- guaifenesin (Mucinex)
- Where
- United States
- Volunteers
- 378 people
- Sponsor
- Reckitt Benckiser Inc.
Influenza
Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958
The purpose of this study is to test the safety and tolerability of an investigational multi-dose inhaled flu medication, CS-8958. Study participants will include 16 males and females, aged 18-55 years of age, inclusive.
- Trial name
- NCT00995826
- Testing
- CS-8958
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Influenza
Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK)
The purpose of this study is to conduct a pilot study to explore the potential use of routinely collected data in General Practitioner (GP) practices to conduct enhanced safety surveillance of seasonal influenza vaccines in the…
- Trial name
- NCT02567721
- Testing
- Vaccine safety surveillance
- Where
- United Kingdom
- Volunteers
- 11,530 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient population.
- Trial name
- NCT04619706
- Testing
- FSD201, Standard of Care for Covid-19
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Quantum Biopharma
Influenza
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old
This is an open study of the use of AdimFlu-V (2012-2013 season) vaccine in young healthy subjects. Subjects aged equal to or over 9 years old and less than 18 years old will receive one dose of vaccine (0.5 mL) by intramuscular…
- Trial name
- NCT01755364
- Testing
- AdimFlu-V
- Where
- Taiwan
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults
Since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profiles of the adjuvanted influenza vaccine need to be re-evaluated after…
- Trial name
- NCT00386698
- Testing
- Fluarix, adjuvanted influenza vaccine
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Safety and Immunogenicity of IVX-A12 in Healthy Older Adults
The main purpose of this study is to evaluate the safety and immunogenicity of three dosage levels (low, medium, high) of the bivalent combination respiratory syncytial virus (RSV)/human metapneumovirus (hMPV) virus-like particle…
- Trial name
- NCT05664334
- Testing
- IVX-121, IVX-241, MF59®
- Where
- 4 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Icosavax, Inc.
COVID-19, SARS-CoV-2 Infection
A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
Trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 (Variant of concern [VOC] strain B.1.351) in BNT162-01 trial participants, or two boosting doses of Comirnaty in…
- Trial name
- NCT04949490
- Testing
- BNT162b2s01, BNT162b2
- Where
- 4 sites in Germany
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Influenza
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)
This study is designed to assess the safety and immunogenicity of a GSK Biologicals' investigational vaccine GSK2321138A in adults 18 years old and older.
- Trial name
- NCT01204671
- Testing
- Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 4,659 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy
This is a point prevalence study conducted entirely in the United States (US) to establish the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses in cystic fibrosis (CF) patients receiving…
- Trial name
- NCT01858519
- Where
- 47 sites in United States
- Volunteers
- 1,310 people
- Sponsor
- AbbVie
Influenza, Healthy
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the…
- Trial name
- FluMist (NCT03143101)
- Testing
- FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
- Where
- 12 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID-19, Cardiovascular Diseases
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
- Conditions
- COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- NCT04615949
- Testing
- Cannabidiol, pharmaceutically produced with < 5 ppm THC
- Where
- 20 sites in United States, Brazil and 1 more
- Volunteers
- 90 people
- Sponsor
- Cardiol Therapeutics Inc.
Respiratory Syncytial Virus (RSV)
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
- Trial name
- NCT07694557
- Testing
- YKYY025 group
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
COVID-19
A Real-World Study of JT001 for COVID-19
Real-world disease outcomes and safety in patients with mild to moderate COVID-19 treated with JT001
- Trial name
- NCT06142201
- Testing
- JT001
- Where
- 6 sites in China
- Volunteers
- 7,656 people
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
COVID-19
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…
- Trial name
- SCB-2019 (NCT04672395)
- Testing
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine, SCB-2019 vaccine
- Where
- 31 sites in Belgium, Brazil and 3 more
- Volunteers
- 31,454 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Influenza Vaccines
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly
A controlled, double-blind study to determine the immunogenicity and safety of influenza cell derived vaccine in elderly subjects.
- Trial name
- NCT01013675
- Testing
- Influenza Vaccine
- Where
- 12 sites in Czechia, Estonia and 1 more
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
COVID-19
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine.
- Trial name
- NCT06680375
- Testing
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA
- Where
- 9 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline